We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Nominations now open for PVRI Achievement Awards 2025
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. The PVRI Lifetime Achievement Award 2025 and the PVRI Achievement Awards 2025 will be presented at PVRI 2025 Rio. Nominate by 25 November 2024.
Our PVRI 2025 Annual Congress 'PVRI 2025 Rio: Embracing Heterogeneity' will be hosted in the vibrant and captivating city of Rio de Janeiro. Taking place 29 January - 1 February 2025, register your place today.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
The PVRI 2025 Annual Congress will be hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe will converge in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD. Register your place!
Organised by the leaders of the PVRI LATAM Task Force, the meeting will address the latest advances in diagnosis and management of adult and paediatric PH and explore avenues to increase the partnership of adult and paediatric physicians to improve clinical outcomes and quality of life for PH patients across the entire lifespan.
'Co-Infection' is part of the Microbes Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
Webinar presentations: The PAH microenvironment: lessons learned from tumor microenvironment mechano-induced cell metabolism changes; Identification of arterial and venous morphologic markers in pulmonary arterial hypertension using CT imaging; The keto diet as treatment for pulmonary hypertension associated with obesity; Endothelial transdifferential from exacerbated inflammatory signaling in BMP9 in lung endothelium; The role of pericytes in the pathophysiology of pulmonary arterial hypertension
Right ventricular (RV) (dys)function determines outcomes in pulmonary hypertension (PH). We previously found that asymmetric RV myocardial work (MW) corresponds with inefficient RV function in experimental PH models. We therefore aimed to investigate regional distribution of RV MW and its correlation with catheter hemodynamics in children with PH.
Activation of the sympathetic nervous system is observed in pulmonary arterial hypertension patients. This study investigates whether inhibiting the conversion of dopamine into noradrenaline by dopamine β-hydroxylase (DβH) inhibition with BIA 21-5337 improved right ventricular (RV) function or remodeling in pressure overload-induced RV failure. RV failure was induced in male Wistar rats by pulmonary trunk banding (PTB).
Data from invasive CPET (iCPET) revealed long COVID patients have impaired systemic oxygen extraction (EO2), suggesting impaired mitochondrial ATP production. However, it remains uncertain whether the initial severity of SARS-CoV-2 infection has implications on EO2 and exercise capacity (VO2) nor has there been assessment of anerobic ATP generation in long COVID patients.
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. They celebrate notable achievements made by special individuals across the world. The PVRI Lifetime Achievement Award 2025 and the PVRI Achievement Awards 2025 will be presented at PVRI 2025 Rio.
Hot topics from PVRI GoDeep, led by Werner Seeger, is a session in the PVRI 2025 programme and will take place on Saturday, 1 February 2025. Presentations include: Overview of the GoDeep meta-registry; Risk scores beyond group 1 PH – baseline and follow-up; Survival outcomes and impact of targeted PAH therapy in PoPH; PAH-targeted therapies in group 3 PH – PDE5 inhibitor therapy associated with improved survival; Male survival disadvantage in PH: independent of etiology, age, disease severity, comorbidities and treatment, but race-dependent
On 27 September 2024, phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS) closed. The survey was first launched in October 2023 to help clinicians better understand the impacts of PH on patients.
This World Heart Day, PVRI supports the WHF campaign calling for increased awareness, better healthcare policies and more funding for heart health research.
